American Association for Cancer Research

Press Releases: 2012

Scientists Reprogram Cancer Cells With Low Doses of Epigenetic Drugs


March 27, 2012

Bookmark and Share

  • Drugs previously considered too toxic for human use.
  • Cancer stem cells were a target of these agents.
  • Study by Stand Up To Cancer Dream Team published in Cancer Cell.
CHICAGO — Experimenting with cells in culture, researchers at the Johns Hopkins Kimmel Cancer Center have breathed possible new life into two drugs once considered too toxic for human cancer treatment. The drugs, azacitidine and decitabine, are epigenetic drugs and work to correct cancer-causing alterations that modify DNA.

The researchers also found that the drugs took aim at a small but dangerous subpopulation of self-renewing cells, sometimes referred to as cancer stem cells, which evade most cancer drugs and cause disease recurrence and spread.

In a report published in the March 16, 2012, issue of Cancer Cell, the Johns Hopkins team said their study provides evidence that low doses of the drugs cause antitumor responses in breast, lung and colon cancer cells. They will discuss their work at a Stand Up To Cancer press event on April 1, 2012, at 1:00 p.m. CT in Room 10 A/B/C of the Hyatt Conference Center, adjacent to the McCormick Place Conference Center.

Conventional chemotherapy agents indiscriminately poison and kill rapidly dividing cells, including cancer cells, by damaging cellular machinery and DNA.

“In contrast, low doses of azacitidine (AZA) and decitabine (DAC) may reactivate genes that stop cancer growth without causing immediate cell killing or DNA damage,” said Stephen Baylin, M.D., Ludwig professor of oncology and deputy director of the Johns Hopkins Kimmel Cancer Center in Baltimore, Md.

Many cancer experts had abandoned AZA and DAC in the treatment of common cancers, according to the researchers, because they are toxic to normal cells at standard high doses and there was little research showing how they might work for cancer in general. Baylin and colleagues decided to reevaluate the drugs after low doses of each showed a benefit in patients with a preleukemic disorder called myelodysplastic syndrome (MDS). Johns Hopkins investigators also found benefit with low doses of the drugs in tests with a small number of patients with advanced lung cancer. “This is contrary to the way we usually do things in cancer research,” said Baylin. He noted, “Typically, we start in the laboratory and progress to clinical trials. In this case, we saw results in clinical trials that made us go back to the laboratory to figure out how to move the therapy forward.”

Baylin’s team worked with leukemia, breast and other cancer cell lines and human tumor samples using the lowest possible doses that were effective against the cancers. In all, the investigators studied six leukemia cell lines, seven leukemia patient samples, three breast cancer cell lines, seven breast tumor samples (including four samples of tumors that had spread to the lung), one lung cancer cell line and one colon cancer cell line.  

Researchers treated cell lines and tumor cells with low-dose AZA and DAC in culture for three days and allowed the drug-treated cells to rest for a week. They then transplanted the treated cells and tumor samples into mice and observed continued antitumor responses for up to 20 weeks. This extended response was in line with observations in some patients with MDS who continued to have anticancer effects long after stopping the drug.

The low-dose therapy reversed cancer cell gene pathways, including those controlling cell cycle, cell repair, cell maturation, cell differentiation, immune cell interaction and cell death. Effects varied among individual tumor cells, but the scientists generally saw that cancer cells reverted to a more normal state and eventually died. These results were caused, in part, by alteration of the epigenetic, or chemical, environment of DNA. Epigenetic activities turn on certain genes and block others, according to Baylin.

The research team also tested AZA and DAC’s effect on a type of metastatic breast cancer cell thought to drive cancer growth and resist standard therapies. Metastatic cells are difficult to study in standard laboratory tumor models because they tend to break away from the original tumor and float around in blood and lymph fluids. The research team re-created the metastatic stem cells’ environment and allowed them to grow as floating spheres.  

Baylin and his team are conducting ongoing studies that focus on the precise mechanism of how the drugs work. “Our findings match evidence from recent clinical trials suggesting that the drugs shrink tumors more slowly over time as they repair altered mechanisms in cells and genes return to normal function, and the cells may eventually die,” said Baylin.

The results of clinical trials in lung cancer, led by Johns Hopkins’ Charles Rudin, M.D., and published late last year in Cancer Discovery, a journal of the American Association for Cancer Research, also indicate that the drugs make tumors more responsive to standard anticancer drug treatment. According to researchers, this means that the drugs could become part of a combined treatment approach rather than a standalone therapy and as part of personalized approaches in patients whose cancers fit specific epigenetic and genetic profiles.

Low doses of both drugs are approved by the U.S. Food and Drug Administration for the treatment of MDS and chronic myelomonocytic leukemia. Clinical trials in breast and lung cancer have begun in patients with advanced disease, and trials in colon cancer are planned.

The research was funded by a Specialized Programs of Research Excellence grant for lung cancer from the National Institutes of Health, the Hodson Trust Foundation, the Entertainment Industry Foundation, Lee Jeans, the Samuel Waxman Cancer Research Foundation, the Department of Defense Breast Cancer Research Program, the Huntsman Cancer Foundation and the Cindy Rosencrans Fund for Triple-negative Breast Cancer Research. All of the studies have been accelerated by funding from the Stand Up To Cancer project in partnership with the American Association for Cancer Research.

# # #

Press registration for the AACR Annual Meeting 2012 is free to qualified journalists and public information officers: www.aacr.org/PressRegistration.

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the AACR

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.  
 
For more information about the AACR, visit www.AACR.org.

Media Contact:
Jeremy Moore
(215) 446-7109
Jeremy.Moore@aacr.org
In Chicago, March 31 - April 4:
(312) 528-8206